A patient whose lupus is in remission or who is experiencing low disease activity faces less risk of experiencing additional…
Articles by Jose Marques Lopes, PhD
Rituxan (rituximab) could be a valid alternative to standard of care in systemic lupus erythematosus (SLE) patients with neurological and…
Cognitive impairment is highly prevalent in patients with systemic lupus erythematosus (SLE), a study from Canada finds. The research also…
Levels of distinct immune cells, including certain monocyte subsets, are altered in systemic lupus erythematosus (SLE) patients, research from China…
Interferon-gamma, an endogenous regulator of immune responses, is associated with reduced cerebral volume in…
Damage to small tubes in the kidneys and the tissue that surrounds them is a strong predictor that lupus nephritis patients…
A European initiative called SHARE has issued new international guidelines for the diagnosis, management, and treatment of childhood-onset systemic lupus…
Low levels of red blood cells (anemia) and lymphocytes, a type of white blood cell, are the most frequent hematological disorders…
Results from the Phase 2 BUTTERFLY trial conducted by Pfizer suggest that an antibody against the pro-inflammatory cytokine interleukin-6 (IL-6) may…
The cytokine interleukin 17A (IL-17A), while playing a role in inflammation, may also serve a protective purpose in systemic lupus erythematosus…